Physician profile
Enos Moss
NPI 1548527997
$6,269.63
in general payments reported to CMS, 2019-2025
27 companies · $3,531 in 2025
The $3,531 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,018 · 2022: $63.48 · 2023: $79.19 · 2024: $1,578 · 2025: $3,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,188.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,161.98 | 2021-2025 | |
| Corium, LLC | $736.22 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $726.10 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $492.90 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $382.34 | 2021-2025 | Rexulti |
| Alkermes, INC. | $358.34 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $320.24 | 2021-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $236.32 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $223.14 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $218.17 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $218.09 | 2021-2025 | Trintellix |
| Tris Pharma INC | $195.31 | 2024-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $166.46 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $157.15 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $144.03 | 2021-2025 | Fanapt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $108.30 | 2024 | |
| Sunovion Pharmaceuticals INC. | $96.22 | 2021 | |
| Janssen Pharmaceuticals, INC | $66.48 | 2021-2025 | Spravato |
| Almatica Pharma LLC | $59.39 | 2021-2025 | Loreev Xr |
| Noven Therapeutics, LLC | $54.99 | 2024-2025 | Xelstrym |
| Harmony Biosciences LLC | $40.46 | 2024 | |
| Tms Neurohealth Centers INC. | $21.16 | 2025 | Tms Neurohealth Centers INC. |
| Bausch Health US, LLC | $21.05 | 2024 | Aplenzin |
| Jazz Pharmaceuticals INC. | $20.92 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.24 | 2024 | Rejoyn |
| Vertical Pharmaceuticals, LLC | $14.57 | 2025 | Relexxii |
| Indivior INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enos Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.